Ningxia Womei Biomedical Technology

Ningxia Womei Biomedical Technology is a China-based biotechnology company specializing in the research, development, and large-scale production of high-end biomedical intermediates and active pharmaceutical ingredients (APIs). The company focuses on metabolic diseases, particularly producing key components for GLP-1 receptor agonists used in treating diabetes and obesity. Their facilities are designed to meet international GMP standards, supporting both domestic and global pharmaceutical supply chains. By leveraging advanced synthesis and purification technologies, Ningxia Womei aims to provide cost-effective and high-quality raw materials for the life sciences industry.